Malignant paraganglioma of the urinary bladder: Immunohistochemical study of prognostic indicators

[1]  I. Lancranjan,et al.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas , 1991, Virchows Archiv A.

[2]  N. Kimura,et al.  Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors , 2005, Endocrine pathology.

[3]  Brygida Berse,et al.  Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.

[4]  P. Rustin,et al.  Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. , 2003, Cancer research.

[5]  P. Rustin,et al.  Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. , 2002, The Journal of clinical endocrinology and metabolism.

[6]  P. Corvol,et al.  Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. , 2002, The American journal of pathology.

[7]  W. Young,et al.  Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. , 2002, The Journal of clinical endocrinology and metabolism.

[8]  L. Thompson.  Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.

[9]  J. Luk,et al.  The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas , 2001, Journal of clinical pathology.

[10]  H. Bonjer,et al.  Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. , 2000, The American journal of pathology.

[11]  H. Bruining,et al.  Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? , 2000, The Journal of pathology.

[12]  J. Cheville,et al.  Paraganglioma of the urinary bladder , 2000, Cancer.

[13]  P. Zvára,et al.  Pheochromocytoma of the urinary bladder: update on new diagnostic modalities plus case report. , 2000, Annales d'urologie.

[14]  C. Larsson,et al.  Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. , 2000, The American journal of pathology.

[15]  K. Omata,et al.  Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[16]  B. Scheithauer,et al.  Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas , 1999, Endocrine pathology.

[17]  T. Yoshimoto,et al.  The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas. , 1998, The Journal of endocrinology.

[18]  S. Leung,et al.  Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. , 1998, Human pathology.

[19]  K. Tanikawa,et al.  Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. , 1998, Human pathology.

[20]  R. Weyant,et al.  Prognostic markers in pheochromocytoma. , 1998, Human pathology.

[21]  B. Fenderson,et al.  Relationship of students' perceptions of faculty to scholastic achievement: are popular instructors better educators? , 1997, Human pathology.

[22]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[23]  R. Aguiar,et al.  Molecular and immunohistochemical analysis of P53 in phaeochromocytoma. , 1995, British Journal of Cancer.

[24]  H. Nagura,et al.  Ki-67 is an indicator of progression of neuroendocrine tumors , 1994, Endocrine Pathology.

[25]  S. R. Lin,et al.  Mutations of the p53 gene in human functional adrenal neoplasms. , 1994, The Journal of clinical endocrinology and metabolism.

[26]  M. Brennan,et al.  Comparison of adrenal and extraadrenal pheochromocytomas. , 1993, Surgery.

[27]  P. Unger,et al.  S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. , 1991, Archives of pathology & laboratory medicine.

[28]  S. Steinberg,et al.  Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. , 1990, Human pathology.

[29]  S. Sheps,et al.  Recent developments in the diagnosis and treatment of pheochromocytoma. , 1990, Mayo Clinic proceedings.

[30]  S. Asa,et al.  Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. , 1989, The American journal of pathology.

[31]  R. Lloyd,et al.  Distribution of chromogranin and S100 protein in normal and abnormal adrenal medullary tissues. , 1985, Archives of pathology & laboratory medicine.

[32]  J. Leestma,et al.  Paraganglioma of the urinary bladder , 1971, Cancer.

[33]  H. Macmahon,et al.  Pheochromocytoma of the urinary bladder. , 1953, The New England journal of medicine.